Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2FJE7)

Drug Name

NDI-034858 Drug Info

Synonyms

Zasocitinib; NDI-034858; C293MNS6TQ; 2272904-53-5; UNII-C293MNS6TQ; TAK-279; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo(1(2H),2'-bipyridin)-3-yl)amino)-; (8S)-N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-{[(1P,2'P)-2-oxo-2H-[1,2'-bipyridin]-3-yl]amino}pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((1R,2R)-2-Methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide; zasocitinib [INN]; TAK279; SCHEMBL20678921; GTPL12155; BDBM424361; EX-A7221; NDI034858; US10508120, Compound I-816; US10508120, Compound I-908; MS-28444; HY-150096; CS-0609920; compound I-908 [US20190256519A1]; F96153; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5- [(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5- a]pyrimidine-3-carboxamide; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide; ZSB

Indication

Disease Entry	ICD 11	Status	REF
Psoriatic arthritis	FA21	Phase 2	[1]

Cross-matching ID

PubChem CID: 137441492
TTD Drug ID: DM2FJE7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting TYK2 tyrosine kinase (TYK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deucravacitinib	DMAR1YS	Plaque psoriasis	EA90.0	Approved	[3]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[3]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[3]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[4]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[5]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[5]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[5]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[5]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[5]
Imidazo[4,5-c]pyridine derivative 1	DM4KBZQ	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TYK2 tyrosine kinase (TYK2)	TTBYWP2	TYK2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05153148) A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Nimbus Therapeutics
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
5	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.